Skip to main content

Articles

Page 1 of 4

  1. Li–Fraumeni syndrome (LFS) is an autosomal dominant hereditary disease. It is associated with the loss of function of the p53 protein and an increased risk of malignant tumor development at early age. The most...

    Authors: María del Mar Galera López, Iván Márquez Rodas, Carolina Agra Pujol, Ángela García Pérez, Enrique Velasco Sánchez and Rosa Álvarez Álvarez

    Citation: Clinical Sarcoma Research 2020 10:24

    Content type: Case Report

    Published on:

  2. Solitary fibrous tumor is an unusual fibroblastic mesenchymal neoplasm typically described in the pleura. It may appear anywhere with a varied anatomic distribution and essentially it can develop from any soft...

    Authors: Maitane I. Orue-Echebarria, Laura Garciafília, Luis Rodriguez-Bachiller, Benjamín Díaz-Zorita, Enrique Velasco, Enrique Ramón, Carolina Agra and Arturo Colón Rodríguez

    Citation: Clinical Sarcoma Research 2020 10:23

    Content type: Case Report

    Published on:

  3. We recently reported outcomes from a Scandinavian Sarcoma Group adjuvant study (SSG XX group A) conducted on localized and operable high risk soft tissue sarcoma (STS) of the extremities and trunk wall. SSG XX...

    Authors: Kirsten Sundby Hall, Øyvind S. Bruland, Bodil Bjerkehagen, Elisabet Lidbrink, Nina Jebsen, Hans Hagberg, Karin Papworth, Oskar Hagberg, Clement Trovik, Henrik Bauer and Mikael Eriksson

    Citation: Clinical Sarcoma Research 2020 10:22

    Content type: Research

    Published on:

  4. The local treatment of Ewing sarcoma of bone involves surgery, radiotherapy or both. The selection of treatment depends on the anatomical extent of the tumour, the effectiveness of the proposed treatment, its ...

    Authors: Craig Gerrand, Jessica Bate, Beatrice Seddon, Uta Dirksen, R. Lor Randall, Michiel van de Sande, Paul O’Donnell, John Tuckett, David Peake, Lee Jeys, Asif Saifuddin, Mel Grainger and Jeremy Whelan

    Citation: Clinical Sarcoma Research 2020 10:21

    Content type: Research

    Published on:

  5. Doxorubicin based chemotherapy is standard first line treatment for patients with soft tissue sarcoma. Currently several options to improve survival after doxorubicin based chemotherapy are being studied. This...

    Authors: Arie Jan Verschoor, Saskia Litière, Sandrine Marréaud, Ian Judson, Maud Toulmonde, Eva Wardelmann, Axel LeCesne and Hans Gelderblom

    Citation: Clinical Sarcoma Research 2020 10:18

    Content type: Research

    Published on:

  6. Radically resected early uterine leiomyosarcoma (eULMS) is still marked by a poor prognosis. Adjuvant strategies investigated up to now have not been corroborated by controlled studies. We retrospectively revi...

    Authors: Giovanni Fucà, Chiara Fabbroni, Rosanna Mancari, Sara Manglaviti, Giorgio Bogani, Elena Fumagalli, Rossella Bertulli, Carlo Morosi, Paola Collini, Francesco Raspagliesi, Nicoletta Colombo, Paolo G. Casali and Roberta Sanfilippo

    Citation: Clinical Sarcoma Research 2020 10:17

    Content type: Research

    Published on:

  7. Mesenchymal chondrosarcoma is an exceedingly rare malignancy, accounting for around 5% of all patients with chondrosarcoma. It is a translocation-related sarcoma that tends to have both local and distant recur...

    Authors: Ghazal Tansir, Sameer Rastogi, Adarsh Barwad and Ekta Dhamija

    Citation: Clinical Sarcoma Research 2020 10:16

    Content type: Case Report

    Published on:

  8. Sarcomas are rare and heterogeneous tumours of mesenchymal origin, with over 100 histological subtypes. Paraneoplastic dermatomyositis has rarely been described in sarcoma. This is the first documented case of...

    Authors: Eve Merry, Alannah Smrke, Kapil Halai, Gulam Patel, Khin Thway, Robin L. Jones and Charlotte Benson

    Citation: Clinical Sarcoma Research 2020 10:15

    Content type: Case Report

    Published on:

  9. Lipofibromatosis-like neural tumors (LPF-NT) are a newly identified class of rare mesenchymal neoplasms. Current standard of care therapy is surgical resection alone; there are no chemotherapies or molecular t...

    Authors: Megan Dupuis, Yulei Shen, Christian Curcio, Jeanne M. Meis, Wei-Lien Wang, Behrang Amini, Laurence Rhines, Jacquelyn Reuther, Angshumoy Roy, Kevin E. Fisher, Anthony P. Conley and J. Andrew Livingston

    Citation: Clinical Sarcoma Research 2020 10:14

    Content type: Case Report

    Published on:

  10. Neoadjuvant imatinib for gastrointestinal stromal tumors (GIST) of the rectum can reduce, but may not eliminate, risk of surgical morbidity from permanent bowel diversion. We sought to evaluate the cost-effect...

    Authors: Mohamad Farid, Johnny Ong, Claramae Chia, Grace Tan, Melissa Teo, Richard Quek, Jonathan Teh and David Matchar

    Citation: Clinical Sarcoma Research 2020 10:13

    Content type: Research

    Published on:

  11. Kaposiform haemangioendothelioma is a rare vascular tumor and may involve skin, deep soft tissue or bone. It is a locally aggressive tumor usually seen in infants. Here we report a case of kaposiform hemagioen...

    Authors: Saurav Verma, Ekta Dhamija, Adarsh Barwad, Venkatesan S. Kumar and Sameer Rastogi

    Citation: Clinical Sarcoma Research 2020 10:12

    Content type: Case Report

    Published on:

  12. Soft tissue sarcomas (STS) are rare and heterogeneous tumors making chemotherapy use controversial. Our goal was to identify a subset of patients with primary STS that benefit with the addition of chemotherapy.

    Authors: Victoria T. Rizk, Arash O. Naghavi, Andrew S. Brohl, David M. Joyce, Odion Binitie, Youngchul Kim, John P. Hanna, Jennifer Swank, Ricardo J. Gonzalez, Damon R. Reed and Mihaela Druta

    Citation: Clinical Sarcoma Research 2020 10:11

    Content type: Research

    Published on:

  13. Conventional cytotoxic agents and pazopanib are approved for advanced soft tissue sarcomas but have low response rates and modest survival benefits. Recently, immune checkpoint inhibitors have shown clinically...

    Authors: Shalabh Arora, Sameer Rastogi, Shamim Ahmed Shamim, Adarsh Barwad and Maansi Sethi

    Citation: Clinical Sarcoma Research 2020 10:10

    Content type: Case Report

    Published on:

  14. A randomised phase II trial demonstrated that the addition of olaratumab to doxorubicin significantly increased overall survival (OS) in patients with advanced soft tissue sarcomas (STS) compared to doxorubici...

    Authors: Spyridon Gennatas, Florence Chamberlain, Thomas Carter, Susanna Slater, Elena Cojocaru, Beth Lambourn, Anna Stansfeld, Radha Todd, Mark Verrill, Nasim Ali, Robin L. Jones, Peter Simmonds, Nicola Keay, Heather McCarty, Sandra Strauss, Vassilios Karavasilis…

    Citation: Clinical Sarcoma Research 2020 10:9

    Content type: Research

    Published on:

  15. Lack of using a validated algorithm to select patients is a source of selection bias in oncology studies using administrative claims. The objective of this study to evaluate published algorithms to identify pa...

    Authors: Nicole Princic, Donna McMorrow, Philip Chan and Lisa Hess

    Citation: Clinical Sarcoma Research 2020 10:8

    Content type: Research

    Published on:

  16. Osteosarcoma is a very aggressive primary bone tumour, affecting mainly young populations. Most cases diagnosed have distant macro- and micro-metastases at the time of diagnosis. Surgical resection with neoadj...

    Authors: Argyris C. Hadjimichael, Athanasios F. Foukas, Olga D. Savvidou, Andreas F. Mavrogenis, Amanda K. Psyrri and Panayiotis J. Papagelopoulos

    Citation: Clinical Sarcoma Research 2020 10:7

    Content type: Review

    Published on:

  17. Soft tissue dedifferentiated leiomyosarcoma with heterologous osteosarcomatous component is an extremely rare entity described in only few cases in the literature.

    Authors: Raffaele Gaeta, Davide Matera, Francesco Muratori, Giuliana Roselli, Giacomo Baldi, Domenico Andrea Campanacci and Alessandro Franchi

    Citation: Clinical Sarcoma Research 2020 10:6

    Content type: Case Report

    Published on:

  18. Uterine adenosarcoma (UA) is an extremely rare sarcoma subtype. There has been limited evaluation of the immune microenvironment in these tumors. The objective of this study is to examine and describe the immu...

    Authors: Ali Mohammed Refaat Ali, Jen-Wei Tsai, Cheuk Hong Leung, Heather Lin, Vinod Ravi, Anthony P. Conley, Alexander J. Lazar, Wei-Lien Wang and Michael J. Nathenson

    Citation: Clinical Sarcoma Research 2020 10:5

    Content type: Research

    Published on:

  19. Well- and dedifferentiated liposarcoma (WD/DDLPS) are rare mesenchymal malignant tumors that account for 20% of all sarcomas in adults. The WD form is a low-grade malignancy with a favourable prognosis which m...

    Authors: Anastassia Serguienko, Peder Braadland, Leonardo A. Meza-Zepeda, Bodil Bjerkehagen and Ola Myklebost

    Citation: Clinical Sarcoma Research 2020 10:4

    Content type: Research

    Published on:

  20. Autologous dendritic cells (DC) loaded with tumor-associated antigens (TAAs) are a promising approach for anticancer immunotherapy. Polyantigen lysates appear to be an excellent source of TAAs for loading onto...

    Authors: Anna Danilova, Vsevolod Misyurin, Aleksei Novik, Dmitry Girdyuk, Natalia Avdonkina, Tatiana Nekhaeva, Natalia Emelyanova, Nino Pipia, Andrey Misyurin and Irina Baldueva

    Citation: Clinical Sarcoma Research 2020 10:3

    Content type: Research

    Published on:

  21. To report on our experience using a simple optional form to facilitate communication on late effects between the patients and the oncologists during outpatient follow-up and to detail on the spectrum of challe...

    Authors: Ivar Hompland, Lena Fauske, Geir Fagerjord Lorem and Øyvind S. Bruland

    Citation: Clinical Sarcoma Research 2020 10:2

    Content type: Research

    Published on:

  22. Regorafenib is a multi-kinase inhibitor approved as third line treatment for metastatic GIST. Dose limiting toxicities are frequently seen and many patients require dose reductions. This study aimed to evaluat...

    Authors: Florence Chamberlain, Sheima Farag, Constance Williams-Sharkey, Cecilia Collingwood, Lucia Chen, Sonia Mansukhani, Bodil Engelmann, Omar Al-Muderis, Dharmisha Chauhan, Khin Thway, Cyril Fisher, Robin L. Jones, Spyridon Gennatas and Charlotte Benson

    Citation: Clinical Sarcoma Research 2020 10:1

    Content type: Research

    Published on:

  23. Sarcomas are a rare, heterogeneous group of tumors with variable tendencies for aggressive behavior. Molecular markers for prognosis are needed to risk stratify patients and identify those who might benefit fr...

    Authors: Nam Q. Bui, Joanna Przybyl, Sally E. Trabucco, Garrett Frampton, Trevor Hastie, Matt van de Rijn and Kristen N. Ganjoo

    Citation: Clinical Sarcoma Research 2019 9:12

    Content type: Research

    Published on:

  24. Sarcomatoid carcinoma, or carcinosarcoma, is a neoplasm that contains both sarcomatous and carcinomatous elements. It is an extremely rare cancer most often arising from visceral organs. Here we report the sev...

    Authors: Nicholas King, Keshav Kukreja, Albina Murzabdillaeva, Yasir Ali, Jason Willis, Abhishek Maiti, Hilary Ma and Joan Bull

    Citation: Clinical Sarcoma Research 2019 9:10

    Content type: Case Report

    Published on:

  25. Conventional chondrosarcomas are malignant cartilage tumors considered radioresistant. Nevertheless, retrospective series show a small but significant survival benefit for patients with locally advanced diseas...

    Authors: Yvonne de Jong, Martha Ingola, Inge H. Briaire-de Bruijn, Alwine B. Kruisselbrink, Sanne Venneker, Ieva Palubeckaite, Bram P. A. M. Heijs, Anne-Marie Cleton-Jansen, Rick L. M. Haas and Judith V. M. G. Bovée

    Citation: Clinical Sarcoma Research 2019 9:9

    Content type: Research

    Published on:

  26. Uncoupling protein 1 (UCP1) is a mitochondral protein transporter that uncouples electron transport from ATP production. UCP1 is highly expressed in brown adipose tissue (BAT), including hibernomas, but its ex...

    Authors: Jessica Malzahn, Afroditi Kastrenopoulou, Ioanna Papadimitriou-Olivgeri, Dionysios J. Papachristou, Jennifer M. Brown, Udo Oppermann and Nick A. Athanasou

    Citation: Clinical Sarcoma Research 2019 9:8

    Content type: Research

    Published on:

  27. The legends for Figs. 3 and 5 of the article [1] incorrectly refer to an “all others group”. The corrected legends should read:

    Authors: Jerry W. Call, Yu Wang, Denisse Montoya, Norman J. Scherzer and Michael C. Heinrich

    Citation: Clinical Sarcoma Research 2019 9:7

    Content type: Correction

    Published on:

    The original article was published in Clinical Sarcoma Research 2019 9:4

  28. This study aims to explore how patients with metastatic gastrointestinal stromal tumour (GIST) experience the adverse effects of treatment, as expressed by the individuals themselves.

    Authors: Lena Fauske, Ivar Hompland, Geir Lorem, Hilde Bondevik and Øyvind S. Bruland

    Citation: Clinical Sarcoma Research 2019 9:6

    Content type: Research

    Published on:

  29. The use of imatinib, sunitinib, and regorafenib has transformed the treatment of advanced GIST. Sunitinib and regorafenib improve progression free-survival in the second (2L) and third (3L) line, respectively,...

    Authors: Jerry W. Call, Yu Wang, Denisse Montoya, Norman J. Scherzer and Michael C. Heinrich

    Citation: Clinical Sarcoma Research 2019 9:4

    Content type: Research

    Published on:

    The Correction to this article has been published in Clinical Sarcoma Research 2019 9:7

  30. Activating mutations of the receptor tyrosine kinase KIT are early events in the development of most gastrointestinal stromal tumors (GISTs). Although GISTs generally remain dependent on oncogenic KIT during tumo...

    Authors: Michael C. Heinrich, Janice Patterson, Carol Beadling, Yuexiang Wang, Maria Debiec-Rychter, Barbara Dewaele, Christopher L. Corless, Anette Duensing, Chandrajit P. Raut, Brian Rubin, Tamas Ordog, Matt van de Rijn, Jerry Call, Thomas Mühlenberg, Jonathan A. Fletcher and Sebastian Bauer

    Citation: Clinical Sarcoma Research 2019 9:3

    Content type: Research

    Published on:

  31. Atypical fibroxanthomas (AFX) and pleomorphic dermal sarcomas (PDS) are lesions of the skin with overlapping histologic features and unspecific molecular traits. PDS behaves aggressive compared to AFX. Thus, a...

    Authors: Christian Koelsche, Damian Stichel, Klaus G. Griewank, Daniel Schrimpf, David E. Reuss, Melanie Bewerunge-Hudler, Christian Vokuhl, Winand N. M. Dinjens, Iver Petersen, Michel Mittelbronn, Adrian Cuevas-Bourdier, Rolf Buslei, Stefan M. Pfister, Uta Flucke, Gunhild Mechtersheimer, Thomas Mentzel…

    Citation: Clinical Sarcoma Research 2019 9:2

    Content type: Research

    Published on:

  32. Doxorubicin is one of the most active drugs available for the treatment of sarcoma. Pegylated-liposomal doxorubicin (PLD) is a formulation of doxorubicin in which the doxorubicin is encapsulated in liposomes c...

    Authors: Malvi Savani, Paari Murugan and Keith M. Skubitz

    Citation: Clinical Sarcoma Research 2019 9:1

    Content type: Case Report

    Published on:

  33. Dedifferentiated chondrosarcomas (CS) are a high-grade variant of CS that confers a 5-year survival of around 10–24%. Dedifferentiated CS arising from the pelvis confers an even worse prognosis.

    Authors: Johnathan R. Lex, Scott Evans, Jonathan D. Stevenson, Michael Parry, Lee M. Jeys and Robert J. Grimer

    Citation: Clinical Sarcoma Research 2018 8:23

    Content type: Research

    Published on:

  34. Relapsed and refractory sarcomas continue to have poor survival rates. The cancer stem cell (CSC) theory provides a tractable explanation for the observation that recurrences occur despite dramatic responses t...

    Authors: Matteo M. Trucco, Christian F. Meyer, Katherine A. Thornton, Preeti Shah, Allen R. Chen, Breelyn A. Wilky, Maria A. Carrera-Haro, Lillian C. Boyer, Margaret F. Ferreira, Umber Shafique, Jonathan D. Powell and David M. Loeb

    Citation: Clinical Sarcoma Research 2018 8:21

    Content type: Research

    Published on:

  35. Periostin is a matricellular protein that is expressed in bone and joint tissues. To determine the expression of periostin in primary bone tumours and to assess whether it plays a role in tumour progression, w...

    Authors: Jennifer M. Brown, Akiro Mantoku, Afsie Sabokbar, Udo Oppermann, A. Bass Hassan, Akiro Kudo and Nick Athanasou

    Citation: Clinical Sarcoma Research 2018 8:18

    Content type: Research

    Published on:

  36. We studied two cases of rare fibrous bone tumors, namely desmoplastic fibroma (DF) and low-grade central osteosarcoma (LGCOS) resembling desmoplastic fibroma (DF-like LGCOS). As the clinical presentation, imag...

    Authors: Wangzhao Song, Eva van den Berg, Thomas C. Kwee, Paul C. Jutte, Anne-Marie Cleton-Jansen, Judith V. M. G. Bovée and Albert J. Suurmeijer

    Citation: Clinical Sarcoma Research 2018 8:16

    Content type: Case Report

    Published on:

  37. This report summarizes the proceedings of the 4th European Bone Sarcoma Networking Meeting, held in London, England, on 21 June 2017. The meeting brought together scientific and clinical researchers and repres...

    Authors: Sandra J. Strauss, Jakob Anninga, Rubina Baglio, Daniel Baumhoer, Sam Behjati, Stefan Bielack, Kjetil Boye, Javier M. Broto, Anne-Marie Cleton-Jansen, Andrea Degasperi, Abigail Evans, Franca Fagioli, Marta Fiocco, Nathalie Gaspar, Dominique Heymann, Nadia Hindi…

    Citation: Clinical Sarcoma Research 2018 8:17

    Content type: Meeting Report

    Published on:

  38. Tenosynovial giant cell tumors (TGCTs) or giant cell tumors of tendon sheath are neoplasms that arise in the synovium. They can be categorized as nodular (localized) or diffuse type (D-TGCT). Historically, sur...

    Authors: Nicholas Giustini, Nicholas M. Bernthal, Susan V. Bukata and Arun S. Singh

    Citation: Clinical Sarcoma Research 2018 8:14

    Content type: Case report

    Published on:

  39. Induction chemotherapy by isolated limb perfusion (ILP) with melphalan and tumour necrosis factor-α is an effective strategy to facilitate limb-conserving surgery in locally advanced extremity sarcoma. In a co...

    Authors: Jens Jakob, Henry G. Smith, Michelle J. Wilkinson, Tim Pencavel, Aisha B. Miah, Joseph M. Thomas, Per-Ulf Tunn, Lothar R. Pilz, Dirk C. Strauss, Peter Hohenberger and Andrew J. Hayes

    Citation: Clinical Sarcoma Research 2018 8:12

    Content type: Research

    Published on:

  40. Kaposi’s sarcoma is a low-grade mesenchymal angioproliferative tumor, most commonly observed in immunocompromised individuals, such as HIV-infected patients. Iatrogenic Kaposi’s sarcoma occurs in patients unde...

    Authors: Emilien Billon, Anne-Marie Stoppa, Lena Mescam, Massimo Bocci, Audrey Monneur, Delphine Perrot and François Bertucci

    Citation: Clinical Sarcoma Research 2018 8:11

    Content type: Research

    Published on:

  41. Post-transplant smooth muscle tumors (PTSMTs) are rare mesenchymal neoplasms which occur after solid organ or haematopoietic stem cell transplantation. PTSMT typically consist of Epstein–Barr-virus (EBV)+ smoo...

    Authors: Kristin Teiken, Mark Kuehnel, Jan Rehkaemper, Hans Kreipe, Florian Laenger, Kais Hussein and Danny Jonigk

    Citation: Clinical Sarcoma Research 2018 8:10

    Content type: Research

    Published on:

  42. One of the commonly used systemic agents for the treatment of aggressive fibromatosis is the anti-oestrogen drug tamoxifen. However, data on efficacy and optimum methods of response assessment are limited, con...

    Authors: M. Libertini, I. Mitra, W. T. A. van der Graaf, A. B. Miah, I. Judson, R. L. Jones, K. Thomas, E. Moskovic, Z. Szucs, C. Benson and C. Messiou

    Citation: Clinical Sarcoma Research 2018 8:13

    Content type: Research

    Published on: